Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept vs Glucocorticoids in IgA Nephropathy
NCT06654596Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of telitacicept in IgA nephropathy (IgAN) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Change of 24-hour urine protein at 40 weeks. Started Dec 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06654596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654596.